Novel drug design for Alzheimer’s disease by insilico approach | 687
Drug Designing: Open Access

Drug Designing: Open Access
Open Access

ISSN: 2169-0138

+44 1223 790975

Novel drug design for Alzheimer’s disease by insilico approach

International Conference and Exhibition on Computer Aided Drug Design & QSAR

October 29-31, 2012 DoubleTree by Hilton Chicago-North Shore, USA

Jyothi Vanama1 G. Girija Sankar and C. Sundaramoorthi

Accepted Abstracts: Drug Design

Abstract :

Alzheimer?s disease (AD) is a common neurodegenerative disorder associated with dementia in late adulthood. Apolipoprotien E, a multifunctional protein with central roles in lipid metabolism and neurobiology, has three common isoforms (apoE2, apoE3, apoE4) with different effects on lipid homeostasis and neurobiology. Unlike apoE3 which is the most common isoform, apoE4, is associated with increased risk of developing AD and other neurodegenerative disorders. Even though the molecular level of mechanisms underlying the apoE?s role is not clear, it is evident from the various research data that the apoE?s interact with various factors in different pathways. Thus, an alternative to traditional drug discovery was chosen for designing anti-AD drugs by understanding the structure of the apoE and its impact on the neurodegenerative process by in silico approach to genome analysis and similar protein structure was predicted. Our novel molecular level bioinformatics screening system comprised of various independent assessment procedures that included i. Determining the Structure of apoE gene ii. Building a Swiss PDB model of Binding Site iii. Search databases for Modeled Site iv. Dock new guests and binding sites v. Predicting binding constants vi. Constructing the Ligand We have discovered ten similar molecules for drug-targetable apoE structure by applying selective insilico approach. RESULTS: The results obtained showed that 2-Phenyl-4-quinolinamine is interacting at the lowest energy level with all the amino acids in the potential active site. Findings from this work suggest that 2-phenyl 4-quinolinamine could be the lead molecule in the treatment for AD.

Biography :

Ms. Jyothi having completed her Post graduation in Pharmaceutical Biotechnology from Dr. MGR University is presently a Ph.D scholar at the Andhra University. She has the credit of securing the university first position in post graduation education. She was actively involved in different research projects at her earlier work site and has presented posters and papers in dif ferent national and international conferences.